ImageneBio names Yanina Grant-Huerta as CFO, effective July 20, 2026

On July 20, 2026, ImageneBio, Inc., based in part on the recommendation of Chief Executive Officer Kristin Yarema, Ph.D., appointed Yanina Grant-Huerta as the company's Chief Financial Officer, principal financial officer and principal accounting officer, effective that day.¹ Yarema had been serving as interim principal financial officer until Grant-Huerta's appointment.¹

Grant-Huerta, age 49, previously worked at Atara Biotherapeutics, Inc. (Nasdaq: ATRA) from April 2020 until July 2026, holding financial planning and analysis and accounting roles, most recently as Chief Accounting Officer from March 2025 to July 2026.¹ Before Atara, she spent 14 years at Amgen Inc. in financial planning and analysis roles of increasing responsibility.¹

Under her employment agreement, Grant-Huerta will receive an annual base salary of $450,000 and will be eligible for an annual discretionary bonus of 40% of her base salary.¹ She will also receive a restricted stock unit award for 65,000 shares under the company's 2025 Equity Inducement Plan, with 25% vesting on the one-year anniversary of her start date and the remainder vesting quarterly thereafter.¹ Additionally, she will receive a stock option to purchase 95,000 shares, with 25% vesting after one year and the rest vesting monthly over the following three years.¹

Grant-Huerta will also participate in the company's Severance and Change in Control Plan. If a covered termination occurs during a change in control period, she would receive a lump sum of 12 months' base salary, 100% of her target annual bonus, up to 12 months of continued health benefits, and full accelerated vesting of equity awards.¹ Outside a change in control period, a covered termination would entitle her to 12 months of continued base salary and up to 12 months of health benefits.¹

Separately, effective July 24, 2026, Chief Medical Officer Benjamin Porter-Brown will move from his full-time role to a consulting position¹, continuing as a consulting clinical development expert and strategic advisor.¹